Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Approved Therapeutic Uses of rhGH
The U.S. Food and Drug Administration has approved rhGH for treatment of growth-hormone deficiency, idiopathic short stature, Turner syndrome, Prader-Willi syndrome, and chronic renal insufficiency. It has also been approved to treat infants who are small for their gestational age.
Keywords: indications | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Hardin, DS, Kemp SF, Allen DV. Twenty years of recombinant human growth hormone in children: relevance to pediatric care providers. Clin Pediatr (Phila) 2007;46:279-86.
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.